Genmab — Maj 2023
-
Go´pinse til alle....trods noget skvulp i Genmab aktien:-)
-
epcoritamab data in FL is wild, hope they can file this soon... Primary refractory ORR
97% CMR
87%- Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status. https://meetings.asco.org/abstracts-presentations/218265
-
Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data. https://meetings.asco.org/abstracts-presentations/218272 -Seems odd that double-hit/triple-hit lymphoma is doing as well as other patients in the trial?
-
Advanced cervical cancer therapy: Comparison of contemporary expert and healthcare professional recommendations from an online treatment decision tool. https://meetings.asco.org/abstracts-presentations/226499 In 2L recurrent disease, all experts chose either single-agent immunotherapy (if PD-L1 positive) or tisotumab vedotin (if PD-L1 negative) vs 45% and 40% of HCPs, respectively
-
I very much agree. By the way, this is another very interesting initiative from Genmab: https://anthropology.ku.dk/dep/news/2021/biotech-company-funds-research-project-on-diversity/
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind